<DOC>
	<DOCNO>NCT00454662</DOCNO>
	<brief_summary>The purpose study investigate combination therapy effective reduce incidence cardiovascular event Japanese elderly high-risk hypertensive patient : AT1 subtype angiotensin II receptor antagonist/calcium channel blocker AT1 subtype angiotensin II receptor antagonist/low dose diuretic .</brief_summary>
	<brief_title>Combination OLMesartan CCB Low Dose Diuretics High Risk Elderly Hypertensive Patients Study ( COLM-Study )</brief_title>
	<detailed_description>Recently , antihypertensive combination therapy recommend various guideline additive effect . Combination therapies AT1 subtype angiotensin II receptor antagonist calcium channel blocker low dose diuretic show pharmacological benefit . However , reduction cardiovascular event safety profile combination therapy level antihypertensive target investigate yet . In study , primary objective compare two combination therapy antihypertensive target 140/90mmHg elderly hypertensive patient high cardiovascular risk . Further study detail provide COLM-Study data center Primary Outcomes : A composite fatal non-fatal cardiovascular event : Sudden death ( death endogenous origin within 24 hour acute onset ) ; Cerebrovascular event ( new occurrence recurrence cerebral infarction , cerebral hemorrhage , subarachnoid hemorrhage transient ischemic attack ) ; Coronary event ( new occurrence recurrence myocardial infarction , coronary revascularization [ PCI CABG ] , hospitalization angina pectoris , hospitalization heart failure ) ; Renal dysfunction ( double serum creatinine creatinine ≥2.0 mg/dl , end stage renal disease ) Secondary Outcomes : All death ; Death cardiovascular event ; Effects glucose metabolism ( fast plasma glucose , postprandial glucose , new onset diabetes mellitus ) ; Incidence primary outcome event ; New occurrence atrial fibrillation ; Safety ; Proportion subject withdraw allocate treatment</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Angiotensin II Type 1 Receptor Blockers</mesh_term>
	<mesh_term>Diuretics</mesh_term>
	<mesh_term>Angiotensin II</mesh_term>
	<mesh_term>Angiotensinogen</mesh_term>
	<mesh_term>Calcium Channel Blockers</mesh_term>
	<criteria>Outpatients age 65 year old , less 85 year ( time inform consent ) , regardless sex Systolic blood pressure ( SBP ) ≥140 mmHg diastolic blood pressure ( DBP ) ≥90 mmHg sit position two consecutive measurement clinic use 1 antihypertensive medication . Systolic blood pressure ( SBP ) ≥160 mmHg diastolic blood pressure ( DBP ) ≥100 mmHg sit position two consecutive measurement clinic without antihypertensive medication . Require least one follow medical history risk factor Medical history Cerebrovascular accident : cerebral infarction , brain hemorrhage , subarachnoid hemorrhage（6 month prior registration） Myocardial infarction , coronary revascularization ( PCI CABG ) （6 month prior registration） Angina pectoris ( except patient history hospitalization within 6 month prior registration ) Risk factor Male Current diabetes mellitus , fast glucose ≥ 110mg/dL postprandial glucose ≥ 140mg/dl Hypercholesterolemia ( Total cholesterol ≥ 260mg/dL ) Low HDL cholesterolemia ( HDLC ＜40mg/dL ) Microalbuminuria ( albumin/cr ≥ 30mg/gCr ) proteinuria ( protein ≥ 1＋ ) Left ventricular hypertrophy ( STT change ECG SV1＋RV5 ≥ 35mm , leave ventricular mass index : male ≥ 125 g/m2 , female ≥ 110 g/m2 ) Secondary hypertension malignant hypertension History cerebrovascular accident ( include TIA ) myocardial infarction within 6 month registration Percutaneous coronary intervention ( PCI ) coronary artery bypass grafting ( CABG ) do within 6 month registration schedule History hospitalization angina pectoris heart failure within 6 month registration Severe heart failure ( New York Heart Association [ NYHA ] functional class III severe ) Complications atrial fibrillation , atrial flutter severe arrhythmia Severe hepatic renal dysfunction ( include current treatment dialysis renal dysfunction serum creatinine ≥ 2.0mg/dL ) Not appropriate change study drug current therapy concurrent disease include coronary disease ( i.e . calcium channel blocker , diuretic , etc ) History serious side effect study drug ( AT1 subtype angiotensin II receptor antagonist , calcium channel blocker , diuretic ) Life threaten condition ( malignant tumor , etc ) Not suit study subject judge study physician</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Elderly</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Angiotensin II Type 1 Receptor Blockers</keyword>
	<keyword>Calcium Channel Blockers</keyword>
	<keyword>Diuretics</keyword>
	<keyword>Combination Drug Therapy</keyword>
	<keyword>Diabetes</keyword>
</DOC>